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Middle East respiratory syndrome coronavirus (MERS-
CoV) has caused an ongoing outbreak of severe acute 
respiratory tract infection in humans in the Arabian Peninsula 
since 2012. Dromedaries have been implicated as possible 
viral reservoirs. We used serologic assays to analyze 651 
dromedary serum samples from the United Arab Emirates; 
151 of 651 samples were obtained in 2003, well before 
onset of the current epidemic, and 500 serum samples 
were obtained in 2013. Recombinant spike protein–specific 
immunofluorescence and virus neutralization tests enabled 
clear discrimination between MERS-CoV and bovine 
CoV infections. Most (632/651, 97.1%) dromedaries had 
antibodies against MERS-CoV. This result included all 151 
serum samples obtained in 2003. Most (389/651, 59.8%) 
serum samples had MERS-CoV–neutralizing antibody titers 
>1,280. Dromedaries from the United Arab Emirates were 
infected at high rates with MERS-CoV or a closely related, 
probably conspecific, virus long before the first human 
MERS cases.
Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging pathogen associated with severe 
respiratory symptoms and renal failure in infected patients 
(1,2). Globally, 156 laboratory-confirmed cases of infection 
with MERS-CoV, including 65 deaths, were reported as of 
early November 2013. All human cases were linked to the 
Arabian Peninsula (Saudi Arabia, Jordan, Oman, Qatar, Ku-
wait, and the United Arab Emirates). Imported cases were 
detected in countries in Europe and Africa (United King-
dom, Germany, Italy, France, and Tunisia) (3).
Transmission patterns, including the putative zoonotic 
source of the virus, remain unclear. Hypotheses include 
frequent zoonotic infections with limited subsequent 
human-to-human transmission chains and existence of a 
self-sustained epidemic in humans (4). A recent study found 
evidence to support the existence of epidemiologically 
unlinked cases in a large outbreak in the al-Hasa region, 
Saudi Arabia (5). It was speculated that zoonotic 
introductions of MERS-CoV from an unknown reservoir 
might occur at high rates, in addition to obvious human-to-
human transmission.
Coronaviruses (CoV) are positive-sense RNA 
viruses. Viruses in the genera Alphacoronavirus and 
Betacoronavirus are associated with mammals and show a 
particularly high level of diversification in bats. Viruses in 
the genera Gammacoronavirus and Deltacoronavirus are 
mostly avian-associated viruses (6,7). MERS-CoV belongs 
to Betacoronavirus phylogenetic lineage C that, in addition 
to MERS-CoV, contains 2 distinct bat-associated CoV 
species (HKU4 and HKU5) (1,8).
Insectivorous bats of the family Vespertilionidae 
were recently shown to carry viruses that are probably 
conspecific with MERS-CoV (9). However, the limited rate 
of contact between humans and insectivorous bats makes a 
continuous and frequent acquisition of MERS-CoV from 
bats an unlikely scenario. In a manner similar to observations 
regarding severe acute respiratory syndrome CoV (SARS-
CoV), an intermediate reservoir host might exist from 
which human infections are acquired. Dromedaries from 
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Antibodies against MERS Coronavirus in Dromedaries
different regions in Africa and the Arabian Peninsula have 
been shown to have antibodies against MERS-CoV (10,11). 
Animals from the Arabian Peninsula had high neutralizing 
serum activities overall and reciprocal antibody titers 
<320–1,280, which support recent infection with MERS-
CoV or a highly related virus. Thus, dromedaries might 
serve as intermediate hosts. However, detailed serologic 
studies in countries with actual incidence of MERS-CoV 
infections in humans have not been conducted.
Serologic analysis of CoVs is challenging because 
of cross-reactivity between CoVs infecting the same host 
and the broad distribution of CoVs in diverse mammalian 
species (6,7,12–14). Antibodies directed against some of 
the major antigens of different CoVs are known to cross-
react in standard serologic assays (15,16). Potential cross-
reactivity is a diagnostic challenge because camelids are 
known to be infected with bovine CoV (BCoV), a distinct 
betacoronavirus of phylogenetic lineage A unrelated to 
the MERS-CoV (17,18). As an additional challenge, 
camel immunoglobulins lack a light chain peptide, 
which affects specific physical properties, such as altered 
size and stability, compared with immunoglobulins of 
other mammals (19,20). The influence of this feature on 
serologic assays has not been thoroughly investigated. 
Thus, serologic assays should be applied with caution, and 
different assay formats should be tested concurrently.
We reported a 2-staged approach for MERS-CoV 
serologic analysis in humans (15,16). Expanding upon 
these studies, we used in the present study a recombinant 
MERS-CoV spike protein immunofluroescence assay 
(rIFA) augmented by a validated protein microarray 
(10,21), followed by MERS-CoV–specific neutralization 
assay, to screen 651 dromedary serum samples from 
the United Arabian Emirates. Cross-reactivity against 
clade A betacoronaviruses was assessed by using a 
immunofluorescence assay (IFA) and a BCoV-specific 
neutralization assay. Serum samples obtained in 2003 and 
2013 were compared to obtain information for the time in 
which MERS-related CoV has been circulating in camels.
Methods
Sampling
A total of 651 dromedary (Camelus dromedarius) 
serum samples were systematically sampled in Dubai, 
United Arab Emirates and the surrounding area in 2003 
(collection 4, n = 151) and in 2013 (collections 1A, 1B, 
2, and 3; n = 500). The total number of camels in that 
area was 360,000 in 2010 (22). Fecal samples were also 
available for collections 1A and 1B (n = 182), all obtained 
in 2013. Animals in collection 1B were born and raised at 
the Dubai Central Veterinary Research Laboratory, which 
tests ≈70,000 camels per year (23) and had no contact with 
other camels. Camels in collection 2 were racing camels 
(age range 2–8 years), and camels in collection 3 were adult 
livestock camels originally purchased from Saudi Arabia, 
Sudan, Pakistan and Oman.
Dromedary blood was obtained for routine health 
screening by jugular vein puncture according to standard 
veterinary procedures by trained personnel. For most 
serum samples, animal owners requested sample codes 
to be anonymous. All samples obtained during 2003 and 
2013 were stored at –80°C until further analysis. For 
comparison, 16 serum samples from C. bactrianus camels 
in zoologic gardens in Germany were included in the 
study. All serum samples were shipped in agreement with 
German import regulations.
Recombinant Spike IFA
For screening purposes, an rIFA was used (15,24). 
In brief, Vero B4 cells were transfected with pCG1 
eukaryotic expression vector that contained the complete 
spike sequence of MERS-CoV or human CoV-OC43. Cells 
were fixed 24-h post-transfection with ice-cold acetone/
methanol and stored dry at 4°C. Serum samples were 
applied at a dilution of 1:80 for 1 h at 37°C, which was 
optimal for reducing nonspecific reactions and maintaining 
sensitivity. Secondary detection was conducted by using a 
goat anti-llama IgG fluorescein isothiocyanate–conjugated 
antibody. For some negative serum samples, dilutions of 
1:20 and 1:40 were also tested.
Spike Protein Microarray
A confirmatory assay based on a protein microarray 
was performed as described (10,21) by using the spike S1 
subunits of MERS-CoV, human CoV-OC43, and SARS-
CoV. Serum samples were used at 1:20 dilutions on 
microarray chips. Relative light units were determined by 
using secondary cyanine 5–conjugated goat anti-llama IgG.
MERS-CoV Conventional IFA
A MERS-CoV IFA with infected Vero cells was 
conducted as described (15) by using commercially 
available MERS-CoV IFA slides (EUROIMMUNAG, 
Lübeck Germany). Serum samples were used at dilutions 
of 1:20–1:5,120. Secondary detection was conducted by 
using goat anti-llama fluorescein isothiocyanate–labeled 
IgG (1:200 dilution; Agrisera, Vännas, Sweden).
Serum Neutralization Test
Serum neutralization tests were conducted as described 
(10) by using Vero B4 (MERS-CoV) or PT (BCoV) cells. 
To reduce volumes of serum needed, all neutralization 
tests were performed in a 96-well format. Reactions 
contained 50 PFUs of MERS-CoV (EMC/2012 strain) or 
BCoV (Nebraska strain) in 25 mL of medium mixed 1:1 
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with camel serum diluted in 25 mL serum-free Dulbecco 
minimum essential medium. The starting dilution was 1:40. 
After incubation for 1 h at 37°C, each well was infected for 
1 h at 37°C with a 50 mL virus–serum mixture. Supernatants 
were removed and fresh complete Dulbecco minimum 
essential medium was added. Assays were terminated by 
fixation with 8% paraformaldehyde for 30 min and stained 
with crystal violet after 3 days. Neutralization titers were 
defined as serum dilutions reducing cytopathic effects in 2 
parallel wells.
Detection of Virus Nucleic Acid
Viral RNA was extracted from serum and fecal 
samples by using the MagNA Pure System (Roche, Basel, 
Switzerland) and an input volume of 100 μL of serum 
or fecal material suspended 1:10 in phosphate-buffered 
saline buffer. The elution volume was 100 μL for serum 
and fecal suspensions. To identify CoV-specific nucleic 
acids, 2 generic CoV PCRs were performed as described 
(25–27), followed by subsequent Sanger sequencing of 
the amplified DNA.
Results
To characterize reactivity of camel serum samples 
with MERS-CoV in different assay formats, we chose 
11 camel serum samples with weak and strong reactivity 
predetermined by using a simple IFA. The 11 serum 
samples were titrated in a 2-fold dilution series in all 
applied assays. The reactivity pattern of the MERS-CoV 
spike protein (MERS-S) was compared against that of 
the human CoV-OC43 spike protein (OC43-S). As in our 
previous study (10), human CoV-OC43 was used instead of 
BCoV in these initial experiments because it is serologically 
indistinguishable from BCoV and is not subject to handling 
restrictions of German Animal Diseases Protection 
Act (28). Overall titers against MERS-S were higher 
than those against OC43-S, and several serum samples 
reacted exclusively against 1 of the 2 viruses (Table 1), 
suggesting the absence of general cross-reactivity between 
spike proteins of both viruses by IFA. Typical patterns of 
reactivity observed for camel serum samples are shown in 
the Figure, panel A.
A previously published microarray-based assay that 
used the receptor-binding S1 spike subunit of MERS-CoV 
(MERS-S1), human CoV-OC43 (OC43-S1), and SARS-
CoV (SARS-S1) was also evaluated. In contrast to our 
previous studies (10,21) we chose a lower fluorescence 
intensity cutoff of 4,000 instead of 20,000 relative 
fluorescence units (RFU) to maximize the sensitivity and 
thereby challenge the target specificity. All 3 MERS IFA-
negative serum samples had signal intensities <4000 RFU 
at serum dilutions of 1:20 (Table 1). All rIFA-positive 
serum samples had saturated signals >65,535 RFU. The 
OC43-S1 reactivity pattern across the serum panel was 
comparable with that for the OC43-S rIFA. As expected, all 
serum samples were negative against the SARS-S1 control 
antigen. A comparison of typical reactivity patterns in the 
microarray with those of the IFA is shown in the Figure, 
panel B. Results for the rIFA and protein microarray were 
highly congruent.
The panel of camel serum samples was additionally 
tested in a commercially available IFA that used cells 
infected with MERS-CoV (vIFA) (EUROIMMUN AG). 
The use of whole virus provides additional structural 
and nonstructural protein antigens, including envelope, 
membrane, nucleocapsid, and diverse replicase proteins. 
However, because of conserved features of nonstructural 
proteins among even distantly related CoVs (7,12), 
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Neutralization test titer¶# 
MERS-S OC43-S MERS-S1 OC43-S1 SARS-S1 MERS-CoV MERS-CoV BCoV 
1 – –  2,555 3,868 2,606  –  – 40 
2 – 320  2,770 18,896 2,776  –  – 80 
3 – 640  3,950 65,535 2,751  –  – 160 
4 320 –  65,535 3,921 1,726  640  40 – 
5 >10,240 320  65,535 7,247 2,306  >5,120  2,560 160 
6 5,120 640  65,535 5,069 2,098  2,560  640 160 
7 >10,240 160  65,535 7,179 2,198  >5,120  640 40 
8 5,120 320  65,535 55,826 2,412  >5,120  1,280 160 
9 5,120 >5,120  65,535 65,535 2,087  >5,120  1,280 320 
10 >10,240 320  65,535 22,695 2,303  >5,120  1,280 320 
11 5,120 1,280  65,535 28,391 2,858  >5,120  640 40 
*rIFA, recombinant immunofluorescence assay (antigen used was complete spike protein); RFU, relative fluorescence units; vIFA, Middle East respiratory 
syndrome coronavirus–based immunofluorescence assay (antigen used complete virus); MERS-S, spike protein from Middle East respiratory syndrome 
coronavirus; OC43-S, spike protein from human coronavirus OC34; SARS-S, spike protein from severe acute respiratory syndrome virus; MERS-CoV, 
Middle East respiratory syndrome coronavirus; BCoV, bovine coronavirus; –, negative.  
†Serum dilutions started at 1:20.  
‡Assay was used for screening purposes. 
§RFU <4,000 were considered negative. The serum dilution used in this assay was 1:20 (antigen used was S1 subunit of spike protein). 
¶Serum dilutions started at 1:40. 
#Assay applied for confirmation purposes. 
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cross-reactivity was possible with this assay (15). In 
the tested panel of camel serum samples, vIFA titers 
corresponded well to titers determined by rIFA and 
generally equal to or higher than titers in the rIFA (Table 1). 
Despite the absence of cross-reactivity between MERS-S–
positive and OC43-S–positive serum samples in this test 
(Figure, panel A), in previous studies the vIFA showed 
false-positive results with human CoV-OC43–positive 
serum samples, in particular if used at lower dilutions, such 
as 1:10 or 1:20 (15,16).
To confirm results from affinity assays with results 
from a functional test, we determined endpoint virus 
neutralization titers by using a microneutralization test 
against MERS-CoV and BCoV. In most animals MERS-
CoV serum neutralization titers were higher than titers 
against BCoV (serum samples 4–11) (Table 1). High IFA 
titers generally corresponded with high neutralization titers, 
with exceptions for some BCoV antibody–positive serum 
samples. Divergence between affinity and neutralization 
assays can result from waning neutralizing antibody activity 
for infections that occurred long ago. Neutralization assays 
confirmed the absence of cross-neutralization between 
MERS-CoV and BCoV antibodies in either direction even 
at low dilutions, such as 1:40. However, sample no. 1 (Table 
1) neutralized BCoV at a dilution of 1:40 despite showing 
negative results in all other serologic assays. This finding 
indicates that nonspecific neutralization activities might be 
encountered with camel serum samples, suggesting that 
higher serum dilutions should be used when conducting 
critical investigations such as viral reservoir studies.
On the basis of the validation studies, we investigated 
4 collections of serum samples from dromedaries from 
the United Arab Emirates that were sampled in 2003 and 
2013. For initial screening, we chose the rIFA because of 
its proven sensitivity and decreased chances of generating 
false-positive results. All 667 camel serum samples from 
the United Arab Emirates and Germany were initially 
screened at dilutions of 1:80. A total of 89.0%–100.0% 
of serum samples in 4 collections showed positive results 
(Table 2). Seroprevalence was higher for collections 
from exclusively adult animals (collections 3 and 4) than 
for a collection from young racing camels (2–8 years of 
age, collection 2). Clear seropositive results included 151 
dromedary serum samples obtained in 2003 (collection 
4). All 16 serum samples from German zoologic gardens 
were tested at the same dilution and showed no reactivity 
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Figure. Immunofluorescence and 
microarray reactivity patterns 
for antibodies (SF74, H40, H97, 
and S11) against Middle East 
respiratory syndrome coronavirus 
(MERS-CoV) in serum samples 
from dromedaries, United Arab 
Emirates, 2013. A) Serum samples 
tested against overexpressed 
MERS-CoV spike protein 
(MERS-S), overexpressed human 
CoV-OC43 spike protein (OC43-S), 
and Vero cells infected with MERS-
CoV (MERS-V). Fluorescence 
intensities were evaluated as 
follows: –, negative; +, weakly 
reactive; ++, reactive; +++, strongly 
reactive. Scale bar indicates 20 μm. 
B) Relative fluorescence units 
(RFU) were determined for the 
same serum samples by microarray 
using S1 domains of MERS-CoV 
and human CoV-OC43. 
RESEARCH
in the rIFA. Re-testing at lower dilutions of 1:20 and 1:40 
confirmed absence of reactivity in these serum samples. 
Subcollection 1B contained serum samples from 5 animals 
that were born in, and had never left, a closed animal 
research facility in Dubai; these animals were seronegative.
A confirmatory microneutralization test was conducted 
at dilutions of 1:640 and 1:1,280 for all IFA-reactive serum 
samples. These high dilutions were chosen on the basis 
of our observation of high levels of neutralizing serum 
activity in camels (10). Most (59.8%, 389/651) serum 
samples had high neutralizing titers >1,280 (Table 2). In 
18.4% (120/651) of all serum samples, neutralization titers 
ranged from 640 through 1,280, and 21.8% (142/651) of 
rIFA-positive serum samples had neutralizing titers <640.
To rule out cross-reactivity and to study additional 
exposure of MERS-CoV–positive camels with BCoV 
(17,18), all serum samples having MERS-CoV 
neutralizing titers >640 were tested by using a BCoV-
specific microneutralization assay. At a dilution of 1:640, 
a total of 19.2% (23/120) of MERS-CoV–neutralizing 
serum samples had concomitant neutralizing activities 
against BCoV (Table 3). Of serum samples that had 
MERS-CoV neutralizing antibody titers >1,280, a total 
of 24.2% (94/389) had concomitant neutralizing activities 
against BCoV.
Fecal samples were available for 182 dromedaries 
in collection 1. All samples were tested by using a 
subfamily Coronavirinae–specific broad-range reverse 
transcription PCR (RT-PCR) and a highly sensitive RT-
PCR specific for genus Betacoronavirus phylogenetic 
lineage C. Both assays were specific for the viral RNA-
dependent RNA polymerase gene. Two positive fecal 
samples were identified by both assays. Sequencing of 
amplified cDNA fragments of 182 nt and 404 nt identified 
sequences 99% identical with BCoV strain Mebus 
(GenBank accession nos. KF894801 and U00735.2). 
To further confirm virus identity, we amplified a region 
within the spike protein gene (positions 24303–24702 in 
BCoV strain Mebus) by using RT-PCR and sequencing it. 
Amplicons from both animals were 97% identical at 
nucleotide level with BCoV strain Mebus, indicating 
the presence of BCoV in camels as reported (10). We 
tested all serum samples in the same way by RT-PCR 
and obtained uniformly negative results.
Discussion
We have shown that dromedaries from the United 
Arab Emirates, a country with human cases of MERS-
CoV infection, have antibodies that can neutralize 
MERS-CoV at high rates. Antibodies were detected in 
serum samples obtained in 2013 and in serum samples 
obtained >10 years earlier, which indicated the long-
standing presence of MERS-CoV or a closely related 
virus in dromedaries in that region. Our data add to 
previous studies in which our group and others have 
reported wide antibody prevalence in camels in various 
regions, including Oman, Egypt, and the Canary Islands 
(10,11). A 10% lower seroprevalence in collection 
2, which contained young racing camels, suggests 
that animals might be infected as juveniles. However, 
because only limited data were made available by 
owners, a definite statement awaits confirmation.
The absence of antibodies in a control cohort from 
Germany might be explained by the fact that these animals 
belonged to a different camelid species (C. bactrianus vs. 
C. dromedarius). However, because MERS-CoV has a 
highly conserved receptor structure, we did not assign high 
priority to the hypothesis that the closely related camel 
species C. bactrianus, should be less susceptible than C. 
dromedarius camels to MERS-CoV (29,30). Differences 
in antibody prevalence rates might reflect a restricted 
geographic distribution of the virus, which corresponds 
to our previous finding of a relatively lower prevalence of 
antibodies against MERS CoV in camels from the Canary 
Islands, which have been isolated from their point of origin 
in Africa for many years (10). Therefore, MERS-CoV–like 
viruses in camelids might be spreading across a region 
covering at least the eastern Arabian Peninsula, including 
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Serum dilution, no. (%) positive  
rIFA, MERS-S† 
 
Neutralization test, MERS-CoV 
80 <640 640–1,280 >1,280 
1A 2013 2/M, F A, J Paired serum and 
fecal samples 
177 175 (98.9)  24 (13.6) 74 (41.8) 79 (44.6) 
1B 2013 2/M, F A, J Animals raised at 
CVRL 
5 0  5 (100.0) 0 0 
2 2013 2/M, F 2–8 y Racing camels 100 89 (89.0)  55 (55.0) 3 (3.0) 42 (42.0) 
3 2013 2/M, F A Livestock camels‡ 218 217 (99.5)  23 (10.6) 13 (6.0) 182 (83.5) 
4 2003 1/F A Systematically 
sampled 
151 151 (100.0)  35 (23.2) 30 (19.9) 86 (57.0) 
Total     651 632 (97.1)  142 (21.8) 120 (18.4) 389 (59.8) 
*MERS-CoV, Middle East respiratory syndrome coronavirus; rIFA, recombinant immunofluorescence assay with MERS-CoV spike protein; MERS-S, 
spike protein from MERS-CoV; A, adult; J, juvenile; CVRL, Dubai Central Veterinary Research Laboratory. 
†Fluorescence signal intensity was rated as negative, +, ++, +++, and ++++. 
‡Originally purchased from Saudi Arabia, Sudan, Pakistan, and Oman. 
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Oman, the United Arab Emirates, Egypt, and Morocco from 
where some of the antibody-positive camels described by 
Reusken et al. originated (10). 
The high rates of antibody prevalence in contemporary 
serum samples and samples from 2003 suggest that the 
virus has spread in camelids for some time. However, 
recognition of camelids as the bona fide reservoir for 
MERS-CoV has to await sequencing of camelid-associated 
MERS-related CoV. In this context, only animals infected 
with conspecific viruses can be regarded as reservoirs for 
a given virus. Although neutralization assays can provide 
evidence of infection with a virus belonging to the same 
serotype, no systematic studies have defined whether 
serotypes correlate with CoVs species. Nevertheless, for 
several CoV clades, serotypes defined by neutralization 
assay will not include >1 viral species. Members of the 
species Betacoronavirus 1, including CoV-OC43 and 
BCoV, show cross-neutralization with each other, but the 
closely related sister species (human CoV-HKU1) does not 
show cross-neutralization (31).
Feline CoV (FCoV) comprises 2 subserotypes that 
show limited cross-reactivity but are considered 1 virus 
species. Transmissible gastroenteritis virus of swine shows 
more efficient cross-neutralization with 1 of these FCoV 
subserotypes than the other and is classified as 1 species 
with FCoV even though it is carried by a different host 
(32). Human CoVs 229E and NL63, which form 2 closely 
related sister taxa, do not show cross-neutralization and 
concordantly form 2 different species by genetic criteria 
(33). Therefore, our finding of high neutralizing antibody 
titers in camelids is suggestive (but not evidentiary) of 
the presence of viruses conspecific with MERS-CoV 
in camelids. Final confirmation will depend on the 
identification of virus sequences in camelids, which should 
expectably be closely related to human-specific MERS-
CoV sequences.
Camels probably acquired MERS-CoV at some 
unknown time. Potential sources include bats of the family 
Vespertilionidae, in which a virus with a close phylogenetic 
relationship with MERS-CoV has been detected (9). 
This virus, which is carried by vespertilionid bats of the 
genus Neoromicia, has been confirmed to be conspecific 
with MERS-CoV. Lineage C betacoronaviruses in other 
bat taxa have also been proposed to be related to MERS-
CoV (34,35). However, although these viruses cluster 
phylogenetically with MERS-CoV, they are not conspecific 
with MERS-CoV on the basis of sequence distance criteria, 
such as that were proposed by Drexler et al. (36).
In vespertilionid bats, including those in the genus 
Neoromicia, virus conspecific with MERS-CoV differs 
from human MERS-CoV, even if formally a member 
of the same species. The observed degree of sequence 
divergence between this virus and MERS-CoV makes 
any direct and recent transmission from bats to humans 
seem unlikely. Nevertheless, it cannot be excluded from 
available data that the virus source population in bats has 
not been detected. For example, a recent investigation of 
Rhinolophus bats in China identified viruses with close 
relationships to the bona fide ancestor of SARS-CoV, and 
viruses described in many studies yielded only conspecific 
yet less related viruses (37). In that study, viruses from 
civet cats, which are deemed to be intermediary hosts in 
the transition of SARS-CoV from bats to humans, were 
still more closely related to human SARS-CoV than even 
the closest bat-borne virus.
If camelids should function as intermediary hosts in a 
similar manner, we should expect a virus in camelids that 
has a closer phylogenetic relationship with any bat-borne 
CoV and thus should be easily detectable with available 
RT-PCRs. Larger studies to confirm the presence of 
MERS-CoV in camelids should receive high priority 
so as to define the animal reservoir of MERS-CoV and 
possibly control it by such measures as vaccination 
or control of animal movement. However, before 
implementation of any control measures, whether 
camelids are a continuous source of infection for humans 
needs to be firmly established.
Acknowledgment
We thank Tobias Bleicker for providing excellent technical 
assistance.
The work was supported by a European research project 
on emerging diseases detection and response (EMPERIE; 
www.emperie.eu/emp/) (contract no. 223498) and ANTIGONE 
(contract no. 278976). C.D. has received infrastructural support 
from the German Centre for Infection Research, the German 
Ministry for Research and Education, and the German Research 
Council (grants 01KIO701 and DR 772/3-1).
Mr Meyer is a doctoral student at the Bonn Institute of 
Virology, Bonn, Germany. His research interests are spike 
protein–mediated entry of bat-borne coronaviruses into cells and 
advancement of specific serologic tests for antibodies against 
coronaviruses.
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 20, No. 4, April 2014 557
 
Table 3. BCoV neutralization test results for MERS-CoV–positive 
dromedary serum samples, United Arab Emirates, 2003 and 
2013* 
Collection 
No. BCoV positive/no. MERS-CoV positive 
(serum dilution, %) 
640–1,280 >1,280 
1A 15/74 (20.3) 14/79 (17.7) 
1B 0 0 
2 0/3 (0.0) 14/42 (33.3) 
3 2/13 (15.4) 52/182 (28.6) 
4 6/30 (20.0) 14/86 (16.3) 
Total 23/120 (19.2) 94/389 (24.2) 
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